预约演示
更新于：2025-07-26
Avibactam sodium
阿维巴坦钠
更新于：2025-07-26
概要
基本信息
原研机构 |
在研机构- |
最高研发阶段终止临床3期 |
首次获批日期- |
最高研发阶段(中国)终止 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C7H11N3NaO6S |
InChIKeyAXVUNLXMABVHIF-JBUOLDKXSA-N |
CAS号1192491-61-4 |
关联
12
项与 阿维巴坦钠 相关的临床试验CTRI/2024/11/077239
A phase 2a, 2-part, open-label, non-randomized, multicenter, single and multiple dose trial to evaluate Pharmacokinetics, Safety and Tolerability of Aztreonam and Avibactam plus or minus Metronidazole in neonates and infants from birth to less than 9 months of age with suspected or confirmed infections due to Gram-Negative pathogens requiring intravenous antibiotic treatment. - NIL
NCT06419296
Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam Vs. Other Active Antibiotics. a Multicenter Target Trial Emulation.
ChiCTR2500101318
Study on the pharmacokinetics of ceftazidime and avibactam sodium for injection in the treatment of carbapenem resistance Multicenter observation of clinical efficacy and safety in patients with severe infection with drug gram-negative bacteria Sexual clinical study
100 项与 阿维巴坦钠 相关的临床结果
登录后查看更多信息
100 项与 阿维巴坦钠 相关的转化医学
登录后查看更多信息
100 项与 阿维巴坦钠 相关的专利（医药）
登录后查看更多信息
2,700
项与 阿维巴坦钠 相关的文献（医药）2025-12-31Gut Microbes
A modelling framework to characterize the impact of antibiotics on the gut microbiota diversity
Article
作者: de Gunzburg, Jean ; Burdet, Charles ; Corbel, Tanguy ; Ferreira, Stéphanie ; Olivares, Carlos ; Guedj, Jeremie ; Ruppé, Etienne ; Andremont, Antoine
Metagenomic sequencing deepened our knowledge about the role of the intestinal microbiota in human health, and several studies with various methodologies explored its dynamics during antibiotic treatments. We compared the impact of four widely used antibiotics on the gut bacterial diversity. We used plasma and fecal samples collected during and after treatment from healthy volunteers assigned to a 5-day treatment either by ceftriaxone (1 g every 24 h through IV route), ceftazidime/avibactam (2 g/500 mg every 8 h through IV route), piperacillin/tazobactam (1 g/500 mg every 8 h through IV route) or moxifloxacin (400 mg every 24 h through oral route). Antibiotic concentrations were measured in plasma and feces, and bacterial diversity was assessed by the Shannon index from 16S rRNA gene profiling. The relationship between the evolutions of antibiotic fecal exposure and bacterial diversity was modeled using non-linear mixed effects models. We compared the impact of antibiotics on gut microbiota diversity by simulation, using various reconstructed pharmacodynamic indices. Piperacillin/tazobactam was characterized by the highest impact in terms of intensity of perturbation (maximal [IQR] loss of diversity of 27.3% [1.9; 40.0]), while moxifloxacin had the longest duration of perturbation, with a time to return to 95% of baseline value after the last administration of 13.2 d [8.3; 19.1]. Overall, moxifloxacin exhibited the highest global impact, followed by piperacillin/tazobactam, ceftazidime/avibactam and ceftriaxone. Their AUC between day 0 and day 42 of the change of diversity indices from day 0 were, respectively, -13.2 Shannon unit.day [-20.4; -7.9], -10.9 Shannon unit.day [-20.4; -0.6] and -10.1 Shannon unit.day [-18.3; -4.6]. We conclude that antibiotics alter the intestinal diversity to varying degrees, both within and between antibiotics families. Such studies are needed to help antibiotic stewardship in using the antibiotics with the lowest impact on the intestinal microbiota.
2025-12-01MOLECULAR BIOLOGY REPORTS
Prevalence of New Delhi Metallo-β-lactamase (blaNDM) gene in a selected population of drug-resistant clinical isolates
Article
作者: Ahmed, Iftikhar ; Saeed, Muhammad ; Ahmad, Aftab ; Shafiq, Muhammad ; Latif, Kunza ; Hyder, Muhammad Zeeshan
OBJECTIVES:
Drug-resistant Enterobacterales carrying carbapenem-resistant genes cause severe infections in clinical settings worldwide. Among these, the New Dehli Metallo-β-lactamase (blaNDM) gene is significantly prevalent and associated with high morbidity. This study was designed to investigate the susceptibility profiling of Carbapenem-Resistant-Enterobacterales (CRE), prevalence of blaNDM and its variants, and associated risk factors.
METHODS:
CRE isolates from a tertiary care hospital, in Islamabad, Pakistan, were identified and the susceptibility testing was performed using disc diffusion method. MICs were determined for imipenem, tigecycline, and colistin through E-strips and microbroth dilution method respectively. For molecular characterization and typing of the blaNDM gene, PCR products were sequenced, and the phylogenetic analysis was performed using MEGA ver 6.0 software.
RESULTS:
Among 5,134 clinical samples, 42.13% (n = 2,163) yielded pathogens including 42.58% (n = 921) Enterobacterales. On further screening, 39.52% (n = 364) of Enterobacterales were identified as CRE. The blaNDM gene was detected in 75.27% (n = 274) in CRE isolates, comprising blaNDM-1 (44%), blaNDM-5 (53%), and blaNDM-7 (3%) variants. Tigecycline (86.7%) and colistin (100%) were most effective antimicrobial agents with MICs ranging from 0.064 to 8 and 0.125-1 µg/ml respectively. blaNDM-1-harboring bacteria exhibited high antimicrobial resistance compared to blaNDM-5 and blaNDM-7. Cefiderocol was 75.6% and ceftazidime/avibactam with aztreonam was 97.08% effective against blaNDM-harboring bacteria. The phylogenetic analysis indicated that blaNDM variants showed close genetic relationships and homology to the previously described sequences in GenBank databases having diverse connection with worldwide sequences.
CONCLUSION:
The high prevalence of blaNDM in our study has of great concern for clinical practice and public health. Clinicians are left with few therapeutic options. However, ceftazidime/avibactam with aztreonam may show therapeutic success. Continuous surveillance is crucial to monitorgenetic variations of continuously evolving blaNDM gene, which is essential for effective clinical management.
2025-11-01DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Evaluation of imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam and cefepime-zidebactam activities on a wide collection of French clinical Enterobacterales isolates
Article
作者: Grillon, Antoine ; Doucet-Populaire, Florence ; Dubois, Véronique ; Leyssene, David ; Robin, Frédéric ; Cattoir, Vincent ; Petillon, Camille ; Brieu, Nathalie ; Carricajo, Anne ; Lemaitre, Nadine ; Podglajen, Isabelle ; Recule, Christine ; Ploy, Marie-Cécile ; Lanotte, Philippe ; Neuwirth, Catherine ; Guérin, François ; Dauwalder, Olivier ; Degand, Nicolas ; Ululuipalelei, Mauli ; Aissa, Nejla ; Bonnet, Richard ; Dortet, Laurent ; Bret, Laurent ; Patry, Isabelle ; Rouis, Karama ; Beyrouthy, Racha ; Proust, Simon ; Réseau, Onerba ; Robert, Jérôme
In recent years, novel β-lactam-inhibitor combinations (imipenem-relebactam (I/R), meropenem-vaborbactam (M/V), aztreonam-avibactam (A/A)) have been commercialized and some are not yet on the market (cefepime-zidebactam (C/Z)). The objective of this study was to evaluate the efficacy of these β-lactam-β-lactamase inhibitors (BL/BLIs) combinations against a wide collection of French clinical multiresistant Enterobacterales isolates and to assess the performance of the E-test MIC method for I/R and M/V. BL/BLIs MICs were determined by broth microdilution on a collection of 200 ESBL-producing and 414 carbapenem-resistant clinical Enterobacterales (K. pneumoniae (271), E. coli (245), E. cloacae complex (48), other species (50)) including 292 carbapenemase-producing isolates. E-test method was evaluated for the determination of I/R and M/V MICs using 131 isolates from this collection. All the combinations were active against most ESBL-producing isolates (99-100 %), but C/Z and A/A MIC90 were lower than that of I/R and M/V (2mg/L and 2mg/L versus 8mg/L and 8mg/L). The M/V and I/R E-tests performances were close to those required by the FDA recommendations: Categorical agreement (CA) and Essential agreement (EA) ≥ 90 %, Major discrepancy (MD) and Very major discrepancy (VMD) < 3 %): 96.9 % (CA), 92.4 % (EA), 1.2 % (MD), 6.1 % (VMD) for I/R and 94.7 % (CA), 96.9 % (EA), 4.1 % (MD), 8.8 % (VMD) for M/V. This work confirmed the interest of C/Z and A/A combinations against carbapenem-resistant Enterobacterales isolates compared with M/V and I/R. Additionally, the findings indicate that the E-test method can be used for the determination of M/V and I/R MIC for E. coli and K. pneumoniae strains.
100 项与 阿维巴坦钠 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 菌血症 | 临床3期 | 美国 | 2020-12-25 | |
| 菌血症 | 临床3期 | 希腊 | 2020-12-25 | |
| 菌血症 | 临床3期 | 印度 | 2020-12-25 | |
| 菌血症 | 临床3期 | 俄罗斯 | 2020-12-25 | |
| 复杂腹腔感染 | 临床3期 | 美国 | 2020-12-25 | |
| 复杂腹腔感染 | 临床3期 | 希腊 | 2020-12-25 | |
| 复杂腹腔感染 | 临床3期 | 印度 | 2020-12-25 | |
| 复杂腹腔感染 | 临床3期 | 俄罗斯 | 2020-12-25 | |
| 复杂下尿路感染 | 临床3期 | 美国 | 2020-12-25 | |
| 复杂下尿路感染 | 临床3期 | 希腊 | 2020-12-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用